Recursion Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-11-05
- Employees
- 500
- Market Cap
- $2.1B
- Website
- http://www.recursion.com
- Introduction
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Recursion Announces Two Key Investigational Oncology Drugs
Recursion announced MHRA and FDA clearances for Phase 1 trials of REC-3565, a MALT1 inhibitor for B-cell malignancies, and REC-4539, a reversible LSD1 inhibitor for small-cell lung cancer. REC-3565 aims to reduce hyperbilirubinemia risk, while REC-4539 targets both peripheral disease and brain metastases.
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials
Recursion announced MHRA and FDA clearances for clinical trials of REC-3565, a MALT1 inhibitor for B-cell malignancies, and REC-4539, a reversible LSD1 inhibitor for small-cell lung cancer. REC-3565 aims to reduce hyperbilirubinemia risk, while REC-4539 targets both peripheral disease and brain metastases. Both drugs represent advancements in precision oncology.
Recursion Announces Two Key Investigational Oncology Developments
Recursion announced MHRA and FDA clearances for Phase 1 trials of REC-3565, a MALT1 inhibitor for B-cell malignancies, and REC-4539, a reversible LSD1 inhibitor for small-cell lung cancer. REC-3565 aims to reduce hyperbilirubinemia risk, while REC-4539 targets brain metastases. Both drugs represent advancements in precision oncology.
Recursion Announces Two Key Investigational Oncology Advancements
Recursion announced MHRA and FDA clearances for clinical trials of REC-3565, a MALT1 inhibitor for B-cell malignancies, and REC-4539, a reversible LSD1 inhibitor for small-cell lung cancer. REC-3565 aims to reduce hyperbilirubinemia risk, while REC-4539 targets both peripheral disease and brain metastases. Both drugs represent advancements in precision medicine, leveraging Recursion's AI-driven drug discovery platform.
From Promise to Practice: Danaher Gathers Visionaries to Discuss AI-Driven R&D
Eric Topol, MD, highlighted AI's potential in healthcare at Danaher's summit, emphasizing its role in improving diagnostics, patient care, and drug discovery. Despite challenges like ethical guidelines and trust, AI's rapid advancement, exemplified by tools like AlphaFold and ChatGPT, is transforming medicine. Experts advocate for embracing AI to enhance healthcare outcomes.
General Proximity: $16 Million (Seed) Raised To Innovate Induced Proximity Medicines For Targeting Undruggable Proteins
General Proximity, a biotech company, emerged from stealth with its OmniTAC platform for induced proximity medicines, raising $16M. Backed by notable investors and a team of top scientists, it aims to target undruggable proteins in diseases like cancer and neurodegeneration, leveraging biological proximity for drug discovery.
Seven Biopharma Trends to Watch in 2025
75% of C-suite executives in life sciences are optimistic about 2025, citing growth and innovation. AI in biopharma is expanding, with increased investments and partnerships. Cancer vaccines and gene editing are advancing, with late-stage trials and new therapies. VC and IPO markets are rebounding, and M&A activity is expected to increase. Multiomics tools are expanding, and spatial biology is consolidating. Regulatory changes under Trump 2.0 may impact biopharma and health policy.
Related Clinical Trials:
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.1% – Here’s What Happened
Recursion Pharmaceuticals shares slightly dropped to $6.76, with a 74% increase in trading volume. Analysts set a $11.00 target price, maintaining a 'Hold' consensus. The company reported a miss in quarterly earnings but a significant revenue increase. Insiders sold shares, while institutional investors increased stakes. Recursion focuses on drug discovery through technology integration.
© Copyright 2025. All Rights Reserved by MedPath